Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 8/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 9/20 | 0.65 |
| ▸ | CA1 | P00915 | 7/20 | 0.54 |
| ▸ | CA2 | P00918 | 7/20 | 0.54 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16196163 | 0.95 | CA9 (0.59) | CA9PDPK1CA1CA2HTR6 | |
| SCHEMBL16196229 | 0.93 | PDPK1 (0.74) | CA9PDPK1CA1CA2 | |
| SCHEMBL16196243 | 0.89 | PDPK1 (0.67) | CA9PDPK1CA1CA2 | |
| SCHEMBL16196303 | 0.83 | CA9 (0.55) | CA9PDPK1CA1CA2 | |
| SCHEMBL16200829 | 0.83 | PDPK1 (0.59) | CA9PDPK1HTR6ADORA3ADORA2A | |
| SCHEMBL12054881 | 0.81 | PDPK1 (0.75) | CA9PDPK1 | |
| SCHEMBL16196304 | 0.80 | PDPK1 (0.80) | PDPK1 | |
| SCHEMBL16195916 | 0.80 | PDPK1 (0.56) | CA9PDPK1HTR6ADORA3ADORA2A | |
| Ar-12 SCHEMBL570472 | 0.79 | PDPK1 (1.00) | CA9PDPK1 | |
| Ar-12 SCHEMBL30099806 | 0.79 | PDPK1 (1.00) | CA9PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156790-B2 | Anticancer P21-activated kinase inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140323538-A1 | ANTICANCER P21-ACTIVATED KINASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323538-A1 | ANTICANCER P21-ACTIVATED KINASE INHIBITORS | CDKN1A, CDK2, CDK3 | CA9 1244/4885PDPK1 286/4885CA1 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.